More  than 1.5 billion people worldwide carry elevated Lp(a) levels, a genetically determined cardiovascular risk factor for which no approved treatment exists. This combination of massive prevalence, robust causal evidence and an active therapeutic pipeline, makes Lp(a) research on of the most dynamic and operationally demanding areas for CROs in the coming decade.

Read the article by Javier Ortega, Senior Medical Manager – Pivotal

If you would like to submit a guest blog please email [email protected].